The efficacy and safety of capecitabine plus bevacizumab combination as first-line treatment in elderly metastatic colorectal cancer patients

Ozcelik, M.Odabas, H.Ercelep, O.Yuksel, S.Mert, A. G.Aydin, D.Surmeli, H.Isik, D.Isik, S.Oyman, A.Ustaalioglu, B. B. OvenAliustaoglu, M.Gumus, M.2020-10-222020-10-222016-06-01Ozcelik M., Odabas H., Ercelep O., Yuksel S., Mert A. G. , Aydin D., Surmeli H., Isik D., Isik S., Oyman A., et al., -The efficacy and safety of capecitabine plus bevacizumab combination as first-line treatment in elderly metastatic colorectal cancer patients-, CLINICAL & TRANSLATIONAL ONCOLOGY, cilt.18, ss.617-624, 2016http://hdl.handle.net/20.500.12645/23576The optimal treatment in older persons with metastatic colorectal cancer (mCRC) is complicated by a lack of general agreement. The aim of this study was to evaluate the activity of bevacizumab plus capecitabine combination in elderly mCRC patients who were not suitable for chemotherapy with irinotecan and oxaliplatin-containing regimens.The efficacy and safety of capecitabine plus bevacizumab combination as first-line treatment in elderly metastatic colorectal cancer patientsArticleWOS:0003757883000108494471105610.1007/s12094-015-1408-626459249